15
Apr
2020
Drug Repurposing to Keep COVID19 Patients Out of the ICU
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.